Welcome to our dedicated page for Medirom Healthcare Technologies SEC filings (Ticker: MRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. MEDIROM files annual reports on Form 20-F and furnishes current and interim information on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed insight into the company’s relaxation salon operations, digital preventative healthcare activities, luxury beauty segment, and health-tech initiatives.
Form 6-K reports for MEDIROM frequently include press releases and explanatory notes about key corporate events. Recent examples cover the issuance and closing of Third Unsecured Convertible-Type Corporate Bonds with Share Options, including terms such as interest accrual, maturity dates, conversion options into common shares, and redemption provisions. Other 6-K filings furnish interim financial information, major Key Performance Indicators (KPIs), and updates on equity financing rounds at subsidiary MEDIROM MOTHER Labs Inc.
Through these filings, investors can review how MEDIROM structures its capital and financing, including unsecured short-term bank loans, convertible debt, and bond issuances conducted outside the United States under Regulation S. The filings also describe how proceeds are intended to be used for general corporate or financing purposes, subject to the company’s decisions over time.
Segment disclosures embedded in MEDIROM’s interim reports identify the Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty segments, along with revenue categories such as franchisor-owned outlets, franchise revenue, royalty revenue, sublease revenue, staffing service revenue, and other franchise-related income. These details help readers understand how the MEDIROM Group organizes its operations and reports performance across its salon network and health-tech businesses.
On Stock Titan, each newly furnished MEDIROM Form 6-K or other SEC document is made available with AI-powered summaries that highlight the most important points, such as financing terms, segment information, and material corporate announcements. Real-time updates from EDGAR ensure that filings related to topics like convertible bonds, treasury strategies involving digital assets, and subsidiary equity financings are accessible soon after publication. Users can quickly scan AI-generated explanations of lengthy reports, then open the full text for deeper review when needed.
For investors tracking MRM, this filings page is a central resource for reviewing MEDIROM’s official disclosures on capital structure, segment reporting, and material events as presented in its SEC submissions.
Healthcare Technologies Inc. filed a Form 6-K after entering a Master Service Agreement with Tools for Humanity and the World Foundation to support adoption of World ID in Japan. The company plans to deploy Orb authentication devices across approximately 3,000 locations nationwide, a major expansion from an initially planned 100 locations.
Within its existing operations, Orbs are already installed at more than 150 Re.Ra.Ku wellness centres, with a goal of reaching about 300 centres across the Re.Ra.Ku Group. Beyond company-operated sites, Healthcare Technologies is negotiating with 370 third-party locations and intends to use a standard framework for contracts, branding, privacy protection, and quality control so authentication services are delivered consistently across partner locations.
MEDIROM Healthcare Technologies Inc. reported operational progress in its collaboration with World, a Proof of Human authentication protocol co-founded by Sam Altman and Alex Blania. The company announced that cumulative Proof of Human authentications using the World ID device “Orb” at its Re.Ra.Ku-centered stores in Japan surpassed 20,000 as of December 28, 2025, roughly doubling from 10,000 in about two months. This growth was largely driven by MEDIROM’s 25th anniversary “5-Minute Shoulder Massage Campaign for 250,000 People,” which paired free massage experiences with on-site human verification. MEDIROM plans to continue rolling out Orb devices to 200 salons nationwide, aiming to broaden access to this digital identity infrastructure while leveraging its existing wellness salon network.
MEDIROM Healthcare Technologies Inc. closed its previously announced sale and issuance of an aggregate principal amount of JPY400,000,000 of its Third Unsecured Convertible-Type Corporate Bonds with Share Options to 11 investors on December 12, 2025. Net proceeds are approximately JPY400,000,000, which the company plans to use for general corporate or financing purposes it deems appropriate from time to time.
The bonds were issued and sold outside the United States in reliance on Regulation S under the Securities Act of 1933. The bonds, the common shares issuable upon conversion, and any American Depositary Shares representing those shares have not been registered under U.S. securities laws and may not be offered or sold in the United States without registration or an applicable exemption. The company includes forward-looking statement cautions and incorporates this report by reference into its registration statements on Form S-8 and Form F-3.
Medirom Healthcare Technologies Inc. is issuing third unsecured convertible corporate bonds with share options totaling JPY 400,000,000 to 11 investors through a third-party allotment. The bonds carry a 2.0% annual interest rate from the day after issuance until June 30, 2026, with interest payable in two installments and the principal due on the maturity date, which the company may extend to December 25, 2026. Between December 12, 2025 and June 10, 2026, bondholders may convert bonds into common shares at a conversion price of JPY 343 per share, and the company also has rights to redeem, or repurchase with bondholder consent, before maturity. Medirom expects gross proceeds of JPY 400,000,000 and currently plans to use the funds for general corporate or financing purposes. The bonds are being sold outside the United States under Regulation S and are not registered under U.S. securities laws.
MEDIROM Healthcare Technologies Inc. (MRM) furnished a Form 6-K announcing it issued a press release about the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc.
The company notes this information is furnished, not filed, and is not incorporated by reference except as specifically provided. The press release is included as Exhibit 99.1.
MEDIROM Healthcare Technologies Inc. announced that its Board of Directors approved adopting cryptocurrency as part of the company’s treasury strategy. The announcement is presented in a press release furnished as Exhibit 99.1 to this Form 6-K. The company states the information is furnished, not deemed “filed” under the Exchange Act, and is not incorporated by reference except as specifically provided.
MEDIROM Healthcare Technologies Inc. furnished a Form 6-K stating it issued a press release. The company announced a milestone of over 10,000 verifications using a new technological device at its wellness salons. The report notes the information is furnished, not deemed “filed,” and is not incorporated by reference except as specifically provided.
Medirom Healthcare Technologies Inc. furnished a Form 6-K for October 2025. The filing provides an interim report for the six months ended June 30, 2025 and related Inline XBRL files.
The company states that this Form 6-K, including its exhibits, is incorporated by reference into its Form F-3 registration statement (File No. 333-290161) and will form part of that registration statement unless superseded by later filings.
Medirom Healthcare Technologies Inc. submitted a Form 6-K as a foreign private issuer to furnish a press release dated October 9, 2025. The press release relates to the Series A equity financing round of its subsidiary, MEDIROM MOTHER Labs Inc.
The Form 6-K clarifies that the information, including the attached press release as Exhibit 99.1, is being furnished rather than filed for liability purposes under the U.S. securities laws and will only be incorporated into other filings if specifically referenced.
FAQ
What is the current stock price of Medirom Healthcare Technologies (MRM)?
What is the market cap of Medirom Healthcare Technologies (MRM)?
